title: The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?
abstract: In a prospective study of 20 patients with NMS, those who received dantrolene (2 patients) or bromocriptine (2 patients) or both (4 patients) tended to have a more prolonged course of illness and a greater incidence of sequelae than those treated with supportive care alone. These results do not indicate a useful role for dantrolene or bromocriptine in the treatment of NMS.
authors.affiliation: Department of Psychiatry, McMaster University Medical Centre, Hamilton, Ontario, Canada.
authors.forename: P I
authors.initials: PI
authors.lastname: Rosebush
authors.forename: T
authors.initials: T
authors.lastname: Stewart
authors.forename: M F
authors.initials: MF
authors.lastname: Mazurek
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003422:Critical Care; D003620:Dantrolene / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy*; D009460:Neurologic Examination; D011446:Prospective Studies
chemical_list: D001971:Bromocriptine; D003620:Dantrolene